ep growth exceed robust top line growth oper
leverag theme continu industri enter much less
restrict reimburs environ prefer
superior growth free cash flow yield
invest thesi stock perform ytd driven robust top-
line growth support larg instal base growth driven airsens
mask ii stabl us reimburs iii brightre drive
higher resuppli see scope oper leverag improv
sg potenti grow half rate top line
differ see less gm pressur last
year softer us competit bid stanc ii weaker usdeur
drive benefit higher-gm eur region contribut iii on-going
improv oper leverag via sg
valuat sit vs coverag remain ow sector-
rel basi still prefer stock trade ep vs
australian off-shore growth earner ew-rat
price target revis time sg leverag despit
strong perform see upsid potenti share due
favor exposur weaker audusd ii reason rel valuat
australian growth us med-tech peer iii resili long-term gross
margin us competit bid propos iv underutil
balanc sheet adjust ep price target line
compani guidanc sg like high end rang
low end
assumpt catalyst risk see low-double-digit global devic
mask growth see gm improv
sg fall risk includ tough comp
row devic growth ii gm fail stabilize/improv
despit weak aud-driven tailwind iii moder high row
up/downsid price target
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
exhibit statist resm cdi
price target convert cdi
cdi disclaim page morgan stanley research
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject nasd/nys restrict commun
subject compani public appear trade secur held
profit loss
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
compani data research research estim note provid research coverag list cdi associ underli ordinari share
compani courtesi may includ cdi price target cdi share price aud dollar research report unless otherwis state cdi price target convers calcul use appropri
currenc exchang rate ordinari share versu cdi ratio investor awar calcul take account issu risk associ invest cdi includ limit liquid
vote right dividend volatil currenc exchang rate fluctuat
still see upsid
estim cog gener aud compani report
us benefit on-going weak audusd estim
improv gm everi depreci fx cross rate addit
report us australian cdi depositari instal
australian trade multipl soften audusd weaken
favour valuat vs australian health growth us medic technolog
ep trade price-to-earnings discount despit
expect deliv superior ep compound-annual-growth-rate exhibit
compani data thomson morgan stanley research actual data morgan
compani data thomson morgan stanley research actual data morgan
exhibit gm peak fall sharpli
continu think margin weaken next
year albeit sharpli previou expect
expect margin fall exhibit think
recent rule chang propos competit bid
allevi price pressur durabl
medic equip supplier lead benign price
environ
despit industri wide challeng experienc past
year gm declin therefor
think appropri adopt less aggress view
exhibit bid price set maximum clear price
mean wine bid receiv amount equal
propos chang competit bid
center medicar medicaid servic
propos chang medicar dme fee schedul payment
competit bid cb process think potenti
three posit implic
improv access contract held dme medicar
furnish associ beneficiari equip
expir decemb propos contract
renew begin januari beneficiari may
receiv dme item will supplier industri dilig
suggest result improv patient access increas
volum perhap invers orphan patient issu
observ cb round juli
stabl price environ appear competit bid
may due delay therebi remov key risk
higher reimburs dme shift medium price clear price
mechan re-bid well cpi price increas dme current cb area
could see reimburs move higher togeth fewer bidder mandatori
bind bid indic reimburs outlook custom
stabl sinc
wide dispers outcom
wide dispers outcom
equival base case dcf
us devic growth higher current forecast addit small move
mask turn see upsid poc reach share
appli dcf valuat current forecast includ step
us growth rate associ new product launch decay pa
bear case assum reduct us mask price reduct us unit
growth remain intern level pa poc remain
rate ow market share gain
increas instal base support
futur posit momentum sale
consum enhanc confid
long-term sustain ep growth
product launch without rmd
top line would revert market growth rate
less price declin pa
weather cost increas line cpi
growth rate possibl owe
under-penetr osa suffer co-
high growth high-margin
therapi repeat mask/dispos sale
occur
upsid at-hom diagnosi de-
bottleneck clinic pathway
data uptak competitor next-
traction upcom launch three new
exhibit bear bull device/mask asp gm biggest valu driver
ask turn
pressur
next
ask turn
risk achiev price
advers impact us competit bid
continu loss cpap market share
eur usd continu deterior
exhibit expect result
debt
equiti
view longer-term-depend dcf valuat methodolog
appropri employ determin forward price target
decreas due small downgrad
forecast move line guidanc
main dcf assumpt shown
npv cashflow
valu equiti
share issu
price target convert cdi
investor awar calcul take account
issu risk associ invest adr includ limit
liquid vote right dividend volatil currenc exchang rate
price target deriv base-cas scenario dcf
assum wacc termin growth rate
potenti announc acquisit biotech/vaccines/immunolog
ii industri de-stock possibl price increas
iii uptak kcentra us
lower-than-expect adopt next-gener rcoag product
ii appreci aud usd
iii chang us reimburs environ
price target deriv base-cas scenario dcf
assum wacc termin growth rate
upsid post-nucleu sale backwards-compat processor weaken
next-gener implant launch
downsid reimburs restrict us develop eu strengthen
disappoint uptak new product
